Paper Details

  1. Home
  2. Paper Details

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.

Author: AzmiJay, BradfordEric S, GengBob, GuptaAtul, IkedaMasanori, PriceRobert G, SteinfeldJonathan, YanceySteven W

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Mepolizumab, an anti-IL-5 monoclonal antibody, was well tolerated and effective in children aged 6 to 11 years with severe asthma with an eosinophilic phenotype. The drug reduced blood eosinophil counts and asthma exacerbations and improved asthma control over 52 weeks.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mepolizumab is approved for patients with severe asthma with an eosinophilic phenotype aged 12 or more (United States) or 6 or more (European Union) years, but its long-term use in children aged 6 to 11 years has not yet been assessed. OBJECTIVE: We sought to assess the long-term safety...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaci.2019.08.005

データ提供：米国国立医学図書館（NLM）

Mepolizumab for Severe Asthma in Children: A Journey to Better Breathing

The world of [pediatric asthma] is a complex and challenging one, particularly for children experiencing [severe asthma] with an [eosinophilic phenotype]. This research investigates the long-term safety and efficacy of [mepolizumab], a [monoclonal antibody], in treating this specific type of asthma in children aged [6 to 11 years]. The study employs an [open-label, uncontrolled, repeat-dose extension] design to assess the long-term effects of mepolizumab on [safety, efficacy, and pharmacodynamics]. The results demonstrate a positive benefit-risk profile for mepolizumab, supporting its use in this patient population.

A Beacon of Hope: Mepolizumab for Severe Eosinophilic Asthma in Children

Just as a beacon guides travelers through the vast desert, this study offers hope for children suffering from [severe eosinophilic asthma]. The study's findings demonstrate the safety and efficacy of [mepolizumab] in this patient population, providing a valuable treatment option for improving breathing and quality of life.

Navigating the Desert of Asthma: Finding a Pathway to Better Breathing for Children

The desert of asthma is a difficult terrain to navigate, particularly for children struggling with [severe eosinophilic asthma]. This study provides a glimmer of hope, highlighting the potential of [mepolizumab] to improve breathing and quality of life. The research underscores the importance of continued research and development of effective treatments for childhood asthma.

Dr.Camel's Conclusion

This study provides long-term safety, pharmacodynamic, and efficacy data for mepolizumab in children with severe asthma with an eosinophilic phenotype. The results demonstrate a positive benefit-risk profile for mepolizumab, supporting its use in this patient population.

Date :
  1. Date Completed 2020-06-15
  2. Date Revised 2020-06-15
Further Info :

Pubmed ID

31425781

DOI: Digital Object Identifier

10.1016/j.jaci.2019.08.005

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.